TY - JOUR
T1 - Translation of quantitative imaging biomarkers into clinical chest ct
AU - Kay, Fernando U.
AU - Oz, Orhan K.
AU - Abbara, Suhny
AU - Barbosa, Eduardo J.Mortani
AU - Agarwal, Prachi P.
AU - Rajiah, Prabhakar
N1 - Publisher Copyright:
© RSNA, 2019.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Quantitative imaging biomarkers may enhance the diagnostic, prognostic, and therapy response analysis capabilities of chest CT in ischemic heart disease, lung cancer, and chronic obstructive pulmonary disease and also may be used for opportunistic screening for low bone mass. Quantitative imaging has been proposed as the next frontier in radiology as part of an effort to improve patient care through precision medicine. In 2007, the Radiological Society of North America launched the Quantitative Imaging Biomarkers Alliance (QIBA), an initiative aimed at improving the value and practicality of quantitative imaging biomarkers by reducing variability across devices, sites, patients, and time. Chest CT occupies a strategic position in this initiative because it is one of the most frequently used imaging modalities, anatomically encompassing the leading causes of mortality worldwide. To date, QIBA has worked on profiles focused on the accurate, reproducible, and meaningful use of volumetric measurements of lung lesions in chest CT. However, other quantitative methods are on the verge of translation from research grounds into clinical practice, including (a) assessment of parenchymal and airway changes in patients with chronic obstructive pulmonary disease, (b) analysis of perfusion with dual-energy CT biomarkers, and (c) opportunistic screening for coronary atherosclerosis and low bone mass by using chest CT examinations performed for other indications. The rationale for and the key facts related to the application of these quantitative imaging biomarkers in cardiothoracic chest CT are presented.
AB - Quantitative imaging biomarkers may enhance the diagnostic, prognostic, and therapy response analysis capabilities of chest CT in ischemic heart disease, lung cancer, and chronic obstructive pulmonary disease and also may be used for opportunistic screening for low bone mass. Quantitative imaging has been proposed as the next frontier in radiology as part of an effort to improve patient care through precision medicine. In 2007, the Radiological Society of North America launched the Quantitative Imaging Biomarkers Alliance (QIBA), an initiative aimed at improving the value and practicality of quantitative imaging biomarkers by reducing variability across devices, sites, patients, and time. Chest CT occupies a strategic position in this initiative because it is one of the most frequently used imaging modalities, anatomically encompassing the leading causes of mortality worldwide. To date, QIBA has worked on profiles focused on the accurate, reproducible, and meaningful use of volumetric measurements of lung lesions in chest CT. However, other quantitative methods are on the verge of translation from research grounds into clinical practice, including (a) assessment of parenchymal and airway changes in patients with chronic obstructive pulmonary disease, (b) analysis of perfusion with dual-energy CT biomarkers, and (c) opportunistic screening for coronary atherosclerosis and low bone mass by using chest CT examinations performed for other indications. The rationale for and the key facts related to the application of these quantitative imaging biomarkers in cardiothoracic chest CT are presented.
UR - http://www.scopus.com/inward/record.url?scp=85069295244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069295244&partnerID=8YFLogxK
U2 - 10.1148/rg.2019180168
DO - 10.1148/rg.2019180168
M3 - Article
C2 - 31199712
AN - SCOPUS:85069295244
SN - 0271-5333
VL - 39
SP - 957
EP - 976
JO - Radiographics
JF - Radiographics
IS - 4
ER -